Quorum Innovations Advances Human Microbiome Program

Quorum Innovations Advances Human Microbiome Program

U.S. Patent allowance for Method of identifying a biologically - active composition from a biofilm

SARASOTA, Fla., Oct. 27, 2016  /PRNewswire/ -- Quorum Innovations today announced a major milestone that includes a drug discovery platform to advance the introduction of new treatments for skin, GI, inflammatory and metabolic conditions utilizing human microbiome therapeutics.

Learn more about Quorum Innovations at http://www.quoruminnovations.com

Quorum is pleased that the USPTO has recognized the novelty and importance of this drug discovery process which is the cornerstone of this patent. Quorum expects to accelerate development in a new class of therapeutics utilizing the human microbiome. Quorum Innovations has successfully isolated a unique series of bacterial derived bioactive compounds. They protect the human microbiome by simultaneously decreasing disease-causing bacteria while defending and increasing health-promoting bacteria. Quorum has named these compounds - ProBiomic™ Therapeutics.  Unlike other products on the market today, Quorum bioactives are also sourced from the human microbiome itself, not from foreign sources such as dirt, exotic plants, or animals.  It is grown in biofilm form and then processed such that the bioactive compounds contain no live bacteria. Quorum Innovations ProBiomic™ technology can currently be found in Quorum Innovation's skin care line – BioEsse (www.bioesseprobiotics.com)

About Quorum Innovations

Dr. Nicholas Monsul, MD,  CEO,  and Dr. Eva Berkes, MD, Chief Science Officer, founded Quorum Innovations in 2011.  Quorum Innovation's new drug candidates are extracted from the human microbiome. This creates a new era in immunology and drug discovery.  Once delivered, like native human microbiota in healthy individuals, Quorum Innovation's ProBiomic^TM  Therapeutics act like microbiome-based software to direct human cells to express particular proteins within target tissues.  By matching the particular Probiomic^TM   Therapeutic   to the desired protein effect in the chosen organ of interest, our new human microbiome-based therapeutics have the power to regulate human and human microbiomial physiology like no other therapeutic system today.

If you would like more information about this topic, please contact Dirk Henson at (941) 951-0126 or email at [email protected].

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/quorum-innovations-advances-human-microbiome-program-300352874.html

SOURCE Quorum Innovations